imipramine has been researched along with Fatigue Syndrome, Chronic in 2 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Fatigue Syndrome, Chronic: A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kumar, A | 1 |
Garg, R | 1 |
Staines, DR | 1 |
2 other studies available for imipramine and Fatigue Syndrome, Chronic
Article | Year |
---|---|
Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2009 |
Phosphodiesterase inhibitors may be indicated in the treatment of postulated vasoactive neuropeptide autoimmune fatigue-related disorders.
Topics: Autoimmune Diseases; Cyclic AMP; Fatigue Syndrome, Chronic; Humans; Imipramine; Neuropeptides; Phosp | 2006 |